Align Technology (ALGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$159.37-3.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · ALGN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 4,158.6 | 4,035.0 | 3,999.0 | 3,862.3 | 3,734.6 | 3,952.6 | 2,471.9 | 2,406.8 | 1,079.9 | 1,079.9 | 1,079.9 | 845.5 | 560.0 | 560.0 | 560.0 | 479.7 | 304.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 1,079.9 | 1,079.9 | 845.5 | 560.0 | 560.0 | 560.0 | 479.7 | 304.0 |
| Cost of Revenues | 1,283.5 | 1,324.0 | 1,199.9 | 1,155.4 | 1,100.9 | 1,017.2 | 708.7 | 662.9 | 264.6 | 264.6 | 264.6 | 205.4 | 143.7 | 143.7 | 143.7 | 118.5 | 78.9 |
| Gross Profit | 2,875.1 | 2,711.0 | 2,799.2 | 2,706.9 | 2,633.8 | 2,935.4 | 1,763.2 | 1,743.9 | 815.3 | 815.3 | 815.3 | 640.1 | 416.4 | 416.4 | 416.4 | 361.3 | 225.1 |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 1,780.2 | 1,755.8 | 1,763.2 | 1,703.4 | 1,674.5 | 1,708.6 | 1,200.8 | — | — | — | — | 390.2 | — | — | — | — | — |
| R&D Expenses | 377.6 | 369.9 | 364.2 | 346.8 | 305.3 | 250.3 | 175.3 | 157.4 | 75.7 | 75.7 | 75.7 | 61.2 | 42.9 | 42.9 | 42.9 | 37.2 | 26.2 |
| Operating Income | 620.5 | 545.8 | 607.6 | 643.3 | 642.6 | 976.4 | 387.2 | 542.5 | 248.9 | 248.9 | 248.9 | 188.6 | 85.6 | 85.6 | 85.6 | 90.4 | 15.5 |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.8 | 0.6 | 3.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (0.5) | (3.0) |
| Other Non-Operating Income / Expenses | 4.4 | 23.5 | (18.9) | (19.4) | (48.9) | 32.9 | (11.3) | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 644.2 | 585.3 | 609.0 | 641.2 | 599.1 | 1,012.4 | 378.9 | 562.7 | 242.6 | 242.6 | 242.6 | 186.1 | 84.3 | 84.3 | 84.3 | 89.9 | 17.1 |
| Income Tax Expense | 152.4 | 174.9 | 187.6 | 196.2 | 237.5 | 240.4 | (1,396.9) | 112.3 | 51.2 | 51.2 | 51.2 | 42.1 | 25.6 | 25.6 | 25.6 | 23.2 | (62.9) |
| Net Income | |||||||||||||||||
| Net Income | 491.5 | 410.4 | 421.4 | 445.0 | 362.0 | 772.0 | 1,775.9 | 442.8 | 189.7 | 189.7 | 189.7 | 144.0 | 58.7 | 58.7 | 58.7 | 66.7 | 80.0 |
| Per Share | |||||||||||||||||
| Basic EPS | 6.92 | 5.66 | 5.63 | 5.82 | 4.62 | 9.78 | 22.55 | 5.57 | 2.38 | 2.38 | 2.38 | 1.80 | 0.73 | 0.73 | 0.73 | 0.86 | 1.20 |
| Diluted EPS | 6.92 | 5.65 | 5.62 | 5.81 | 4.61 | 9.69 | 22.41 | 5.53 | 2.33 | 2.33 | 2.33 | 1.77 | 0.71 | 0.71 | 0.71 | 0.83 | 1.18 |
| Revenue per Share | 58.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 71.0 | 72.5 | 74.9 | 76.4 | 78.2 | 78.9 | 78.8 | 79.4 | 79.9 | 79.9 | 79.9 | 80.0 | 80.5 | 80.5 | 80.5 | 78.0 | 66.8 |
| Diluted Weighted Avg Shares | 71.0 | 72.6 | 75.0 | 76.6 | 78.4 | 79.7 | 79.2 | 80.1 | 81.5 | 81.5 | 81.5 | 81.5 | 83.0 | 83.0 | 83.0 | 80.3 | 68.1 |
| Supplemental | |||||||||||||||||
| EBITDA | — | 783.2 | 752.7 | 785.7 | 768.4 | 1,085.1 | 467.3 | 621.5 | 272.9 | 272.9 | 272.9 | 206.6 | 99.0 | 99.0 | 99.0 | 102.5 | 25.5 |
| EBIT | 620.5 | 545.8 | 607.6 | 643.3 | 642.6 | 976.4 | 387.2 | 542.5 | 248.9 | 248.9 | 248.9 | 188.6 | 85.6 | 85.6 | 85.6 | 90.4 | 15.5 |
| Effective Tax Rate | 23.7% | — | — | 30.6% | 39.6% | 23.7% | -368.6% | 20.0% | 21.1% | 21.1% | 21.1% | 22.6% | 30.4% | 30.4% | 30.4% | 25.8% | -368.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.